10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001804220-20-000022`
Period End Date	20200630
Filing Date	20200805
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	regn-20200630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 71 Income Statement 84 Cash Flow Statement 56 Stockholders Equity 43

Balance Sheet 71 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred Stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred Stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred Stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred Stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.62B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.05B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.99B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.15B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.60B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$2.10B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.99B	USD	Point-in-time
Accounts receivable - Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$260.60M	USD	Point-in-time
Accounts receivable - Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$389.20M	USD	Point-in-time
Treasury Stock (in shares)	`TreasuryStockShares`	4.86M	shares	Point-in-time
Treasury Stock (in shares)	`TreasuryStockShares`	15.58M	shares	Point-in-time
Accounts receivable - other	`AccountsAndNotesReceivableNet`	$431.10M	USD	Point-in-time
Accounts receivable - other	`AccountsAndNotesReceivableNet`	$425.00M	USD	Point-in-time
Inventories	`InventoryNet`	$1.64B	USD	Point-in-time
Inventories	`InventoryNet`	$1.42B	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$273.70M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$263.80M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$7.69B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$7.86B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$2.59B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$3.26B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$3.03B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.89B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$774.00M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$824.20M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$144.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$175.50M	USD	Point-in-time
Total assets	`Assets`	$14.81B	USD	Point-in-time
Total assets	`Assets`	$14.43B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$380.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$418.10M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$1.26B	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$1.21B	USD	Point-in-time
Debt	`ShortTermBorrowings`	$1.50B	USD	Point-in-time
Debt	`ShortTermBorrowings`	-	USD	Point-in-time
Other liabilities - Sanofi	`OtherLiabilitiesCurrent`	$103.80M	USD	Point-in-time
Other liabilities - Sanofi	`OtherLiabilitiesCurrent`	$85.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.10B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.70B	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$713.90M	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$715.90M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$317.70M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$457.90M	USD	Point-in-time
Total liabilities	`Liabilities`	$5.37B	USD	Point-in-time
Total liabilities	`Liabilities`	$3.72B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$6.26B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$7.38B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$8.90B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$35.50M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$21.10M	USD	Point-in-time
Treasury Stock, at cost; 15,578,240 shares in 2020 and 4,860,123 shares in 2019	`TreasuryStockValue`	$6.14B	USD	Point-in-time
Treasury Stock, at cost; 15,578,240 shares in 2020 and 4,860,123 shares in 2019	`TreasuryStockValue`	$739.90M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.13B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$11.09B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.44B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.06B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$8.76B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.81B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.43B	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.95B	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.95B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.58B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.78B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$885.50M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.37B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$722.00M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.31B	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$294.60M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$348.30M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$585.70M	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$715.60M	USD	2 Qtrs
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$63.70M	USD	1 Quarter
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$120.40M	USD	2 Qtrs
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$90.60M	USD	2 Qtrs
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$50.20M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.30B	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.26B	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$2.15B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$2.42B	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$656.40M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.36B	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$315.60M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$795.60M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-9.10M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$272.20M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$246.80M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-82.90M	USD	1 Quarter
Interest expense	`InterestExpense`	$8.00M	USD	1 Quarter
Interest expense	`InterestExpense`	$15.70M	USD	2 Qtrs
Interest expense	`InterestExpense`	$15.80M	USD	2 Qtrs
Interest expense	`InterestExpense`	$9.70M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$231.00M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$-90.90M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$262.50M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-24.80M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.59B	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$918.90M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$224.70M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$770.80M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$65.60M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$31.60M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$21.60M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$116.60M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.52B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$1.77	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$13.87	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$6.00	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$8.19	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$7.61	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.69	USD	2 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$1.68	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$13.03	USD	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.20M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.10M	shares	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.60M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.70M	shares	2 Qtrs
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.60M	shares	1 Quarter
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.80M	shares	2 Qtrs
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.00M	shares	2 Qtrs
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	117.90M	shares	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.52B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Unrealized gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$15.80M	USD	2 Qtrs
Unrealized gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$30.50M	USD	2 Qtrs
Unrealized gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$14.40M	USD	1 Quarter
Unrealized gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$44.60M	USD	1 Quarter
Unrealized loss on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-2.40M	USD	2 Qtrs
Unrealized loss on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	-	USD	1 Quarter
Unrealized loss on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-1.40M	USD	1 Quarter
Unrealized loss on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-1.40M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.54B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$941.90M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$682.30M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$206.10M	USD	1 Quarter

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.52B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$103.10M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$114.90M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$213.70M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$209.30M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$175.80M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-110.70M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$125.30M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$-118.00M	USD	2 Qtrs
Increase in Sanofi, trade, and other accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$47.10M	USD	2 Qtrs
Increase in Sanofi, trade, and other accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$247.50M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$233.40M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$168.20M	USD	2 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-33.20M	USD	2 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-33.80M	USD	2 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$78.90M	USD	2 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$129.80M	USD	2 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$381.60M	USD	2 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$20.90M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$431.10M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$119.50M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.64B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.09B	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.53B	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$2.19B	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$2.84B	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$745.90M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$168.90M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$300.00M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.61B	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.01B	USD	2 Qtrs
Proceeds from bridge loan facility	`ProceedsFromShortTermDebt`	$1.50B	USD	2 Qtrs
Proceeds from bridge loan facility	`ProceedsFromShortTermDebt`	-	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$155.10M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$2.17B	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$571.60M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$40.50M	USD	2 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$10.00M	USD	2 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$5.37B	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.28B	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$104.60M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$374.40M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-422.20M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.06B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.00B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.63B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.06B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.00B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.63B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time

Stockholders Equity 43 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$12.13B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$11.09B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.06B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$13.90M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$140.90M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.36B	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$817.40M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$10.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$29.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$416.50M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$155.10M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$10.10M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$14.60M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$10.50M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$11.70M	USD	1 Quarter
Repurchases of Common Stock (in shares)	`TreasuryStockSharesAcquired`	9.81M	shares	Point-in-time
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$54.00M	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$336.00M	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$5.00B	USD	Point-in-time
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$5.07B	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$105.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$108.00M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$109.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$114.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.52B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$654.20M	USD	2 Qtrs
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$13.00M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$44.60M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-30.20M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$15.10M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$12.13B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$11.09B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.06B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.